Skip to Content

Lonza Group Ltd - Stock Quote LONN

Rating as of

Morningstar's Lonza Group Ltd Stock Analysis

Valuation
Currency in CHF
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Lonza Reports Solid Q4 Results; Maintaining Fair Value Estimate of CHF 620, Shares Fairly Valued

Rachel Elfman Equity Analyst

Analyst Note

| Rachel Elfman |

Lonza reported solid year-end results driven by continued growth in its biologics business. Fiscal 2021 revenue totaled CHF 5.4 billion, which represents a 20% increase year over year on an adjusted basis for Lonza’s continuing operations. After updating our valuation model, we maintain our fair value estimate of CHF 620 per share and view shares as fairly valued, currently trading in 3-star territory. We maintain our narrow economic moat rating and stable moat trend.

Read Full Analysis

Lonza Group Ltd's Company Profile

Business Description

Lonza Group is a contract development and manufacturing organization, or CDMO. It operates under four segments: small molecules, biologics, cell & gene, and capsules & health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing services throughout the entire lifecycle of a product from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.

Contact
Muenchensteinerstrasse 38
Basel, 4002, Switzerland
T +41 613168111
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings
Fiscal Year End Dec 31, 2021
Stock Type
Employees 14,405